Original Paper

Journal of Cancer Research and Clinical Oncology

, Volume 132, Issue 10, pp 617-626

First online:

The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer

  • Chuan-Gui SongAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University
  • , Zhen HuAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University
  • , Jiong WuAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University
  • , Jian-Min LuoAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University
  • , Zhen-Zhou ShenAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University
  • , Wei HuangAffiliated withChinese National Human Genome Center at Shanghai
  • , Zhi-Ming ShaoAffiliated withDepartment of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

To investigate the prevalence of BRCA1 and BRCA2 mutations among Chinese patients, we studied 70 Shanghai cases with early onset breast cancer and affected relatives, and mutation screening was performed in the whole-gene sequence of BRCA1 and BRCA2 by polymerase chain reaction-based denaturing high-performance liquid chromatography. Six disease-causing mutations in BRCA1 (8.6%) and two in BRCA2 (2.9%) were detected, including four novel mutations that were all in the BRCA1 gene (3449insA, IVS17-1G>T, IVS21+1G>C and 5587-1del8). Additional sequence variants identified included 30 polymorphisms (18 in BRCA1 and 12 in BRCA2) and a novel mis-sense mutation of unknown significance in BRCA2 (5911G>C). The 9.5 and 2.4% patients with breast cancer diagnosed before the age of 35 were BRCA1- and BRCA2-mutation carriers, and the prevalence of BRCA1 and BRCA2 mutations in the families with two or more affected individuals were 12.1 and 3.0%, respectively. In these families, all the BRCA1 and BRCA2 mutations were detected in the families containing at least one case diagnosed under the age of 40, and in the families whose youngest patients were diagnosed before the age of 35, the prevalence of BRCA1 and BRCA2 were as high as 40 and 20%, respectively. Based on this information, we conclude that genetic testing should be performed among patients with early onset breast cancer (<40 years), especially combined with family history.

Keywords

Breast cancer BRCA1 and BRCA2 Sequence variation DHPLC Chinese